Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC.
1/5 보강
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in the treatment of castration-resistant prostate cancer (CRPC).
APA
Gardner EJ, Ponnusamy S, Adelaiye-Ogala R (2025). Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC.. Frontiers in oncology, 15, 1748527. https://doi.org/10.3389/fonc.2025.1748527
MLA
Gardner EJ, et al.. "Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC.." Frontiers in oncology, vol. 15, 2025, pp. 1748527.
PMID
41602415 ↗
Abstract 한글 요약
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in the treatment of castration-resistant prostate cancer (CRPC). Emerging evidence suggests that Enzalutamide resistance is not solely due to the loss of AR dependency but can also arise from epigenomic reprogramming of the AR cistrome toward noncanonical gene networks. Recent studies have revealed that this reprogramming is mediated by previously unrecognized coactivators, including CXXC5, TET2, and EZH2, which cooperate with AR to establish a transcriptional landscape that supports lineage plasticity and therapeutic evasion. These noncanonical AR transcriptional programs enable CRPC cells to survive under continued AR blockade, acting as a transitional state towards neuroendocrine differentiation. Pharmacologic disruption of these coactivators abrogates noncanonical AR activity and suppresses tumor growth, highlighting a tractable vulnerability. These findings redefine AR signaling in advanced disease, suggesting that targeting noncanonical AR coactivators could offer a novel therapeutic paradigm to overcome resistance. Advances in single-cell and epigenomic profiling are poised to delineate further the heterogeneity and dynamics of AR cistrome remodeling in treatment-refractory prostate cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Preclinical and first-in-human evaluation of novel androgen receptor-targeted PET imaging in prostate cancer.
- Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features.
- Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer.
- Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.